|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hamashima C, Shabana M, Okada K, Okamoto M
and Osaki Y: Mortality reduction from gastric cancer by endoscopic
and radiographic screening. Cancer Sci. 106:1744–1749. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jeung YJ, Ok HJ, Kim WG, Kim SH and Lee
TH: Krukenberg tumors of gastric origin versus colorectal origin.
Obstet Gynecol Sci. 58:32–39. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jiang R, Tang J, Cheng X and Zang RY:
Surgical treatment for patients with different origins of
Krukenberg tumors: Outcomes and prognostic factors. Eur J Surg
Oncol. 35:92–97. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim HK, Heo DS, Bang YJ and Kim NK:
Prognostic factors of Krukenberg's tumor. Gynecol Oncol.
82:105–109. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ayhan A, Guvenal T, Salman MC, Ozyuncu O,
Sakinci M and Basaran M: The role of cytoreductive surgery in
nongenital cancers metastatic to the ovaries. Gynecol Oncol.
98:235–241. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gagnon Y and Têtu B: Ovarian metastases of
breast carcinoma. A clinicopathologic study of 59 cases. Cancer.
64:892–898. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ajani JA, D'Amico TA, Almhanna K, Bentrem
DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fuchs CS, et
al: Gastric Cancer, Version 3.2016, NCCN Clinical Practice
Guidelines in Oncology. J Natl Compr Canc Netw. 14:1286–1312. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kiyokawa T, Young RH and Scully RE:
Krukenberg tumors of the ovary: A clinicopathologic analysis of 120
cases with emphasis on their variable pathologic manifestations. Am
J Surg Pathol. 30:277–299. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Agnes A, Biondi A, Ricci R, Gallotta V,
D'Ugo D and Persiani R: Krukenberg tumors: Seed, route and soil.
Surg Oncol. 26:438–445. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ha HK, Baek SY, Kim SH, Kim HH, Chung EC
and Yeon KM: Krukenberg's tumor of the ovary: MR imaging features.
AJR Am J Roentgenol. 164:1435–1439. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cho JY, Seong CK and Kim SH: Krukenberg
tumor findings at color and power Doppler US; correlation with
findings at CT, MR imaging, and pathology. Case reports. Acta
Radiol. 39:327–329. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Koyama T, Mikami Y, Saga T, Tamai K and
Togashi K: Secondary ovarian tumors: Spectrum of CT and MR features
with pathologic correlation. Abdom Imaging. 32:784–795. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC, et al: New guidelines to evaluate the
response to treatment in solid tumors. European Organization for
Research and Treatment of Cancer, National Cancer Institute of the
United States, National Cancer Institute of Canada. J Natl Cancer
Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Husband JE, Schwartz LH, Spencer J,
Ollivier L, King DM, Johnson R and Reznek R; International Cancer
Imaging Society, . Evaluation of the response to treatment of solid
tumours - a consensus statement of the International Cancer Imaging
Society. Br J Cancer. 90:2256–2260. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vergote I, Rustin GJ, Eisenhauer EA,
Kristensen GB, Pujade-Lauraine E, Parmar MK, Friedlander M,
Jakobsen A and Vermorken JB: Re: New guidelines to evaluate the
response to treatment in solid tumors [ovarian cancer]. Gynecologic
Cancer Intergroup. J Natl Cancer Inst. 92:1534–1535. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rustin GJ, Quinn M, Thigpen T, du Bois A,
Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S, Greven K,
Vergote I, et al: Re: New guidelines to evaluate the response to
treatment in solid tumors (ovarian cancer). J Natl Cancer Inst.
96:487–488. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bubley GJ, Carducci M, Dahut W, Dawson N,
Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G,
et al: Eligibility and response guidelines for phase II clinical
trials in androgen-independent prostate cancer: Recommendations
from the Prostate-Specific Antigen Working Group. J Clin Oncol.
17:3461–3467. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Scher HI, Halabi S, Tannock I, Morris M,
Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ,
Dreicer R, et al; Prostate Cancer Clinical Trials Working Group, .
Design and end points of clinical trials for patients with
progressive prostate cancer and castrate levels of testosterone:
Recommendations of the Prostate Cancer Clinical Trials Working
Group. J Clin Oncol. 26:1148–1159. 2008. View Article : Google Scholar : PubMed/NCBI
|
